Author: Matthew Nelson|| Date Published: August 7, 2020
An SRI International division has secured a potential seven-year, $100M contract to help a National Institutes of Health component develop methods to medical conditions caused by direct exposure or contamination from radioactive materials.
SRI Biosciences will support the National Institute of Allergy and Infectious Diseases in research and development of medical countermeasures for radiological and nuclear emergencies, the nonprofit said Wednesday.
The partnership will also explore biological dosimetry tests and advance candidate treatments for acute radiation syndromes, delayed effects from acute radiation exposure and internal radionuclide contamination.
Both NIH and NIAID have worked with SRI Biosciences to develop radiation therapies as part of a contract slated to expire this month.
Veritas Capital announced that affiliates of its Vantage Fund have agreed to acquire artificial intelligence-enabled digital transformation services provider MetroStar…
Virtualitics announced on LinkedIn Saturday that Nicole Diresta has been appointed vice president for public policy and planning. Diresta will oversee initiatives…
J2 Ventures has closed its $250 million Brookhaven Fund, an oversubscribed early-stage investment vehicle focused on dual-use technologies critical to…
